Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

Johanna C. Bendell , Manish R. Patel , Carrie Baker Brachmann , Xi Huang , Julia D. Maltzman , Victoria Smith , Gregory Sumpao Vosganian , Zev A. Wainberg , Alexander Starodub

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01803282

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 363)

DOI

10.1200/JCO.2017.35.4_suppl.363

Abstract #

363

Poster Bd #

G11

Abstract Disclosures

Similar Posters

First Author: Manish A. Shah

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

First Author: Yan-Shen Shan

Poster

2015 Gastrointestinal Cancers Symposium

Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.

Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.

First Author: Amit Mahipal

First Author: Zev A. Wainberg